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S U M M A R Y 
A total of 54 adult patients with chronic intestinal or hepato-intestinal schis­
tosomiasis mansoni were included into a double-blind clinical trial to compare 
praziquantel and oxamniquine. Following a randomized allocation, 27 patients 
received praziquantel — 65 mg/kg bwt — and 27 oxamniquine — 18 mg/kg bwt — 
in a single oral dose divided into two intakes. The incidence, severity and du­
ration of side-effects were similar for the two drugs. 
The assessment of therapeutical efficacy was based on the quantitative oogram 
technique via biopsy of the rectal mucosa, performed at the end of 1, 2, 4 and 
6 months after treatment. At these same occasions, stool examinations according 
to Hoffman, Pons & Janer (HPJ) and Kato-Katz (K-K) methods were undertaken 
to confront their results with the oogram findings. In order to evaluate the 
immediate effect of the therapy upon the egg laying activity of the parasite, a 
limited number of patients was submitted to rectal biopsies on the 6th. and 
18th. days subsequent to the drug administration. 
Both drugs proved to be active anti-schistosomal agents as their coefficients 
of variation, determined from the oograms made immediatly following the treat­
ment, were above 60%. Furthermore, out of 27 patients in each group, 24 treated 
with praziquantel and 22 with oxamniquine have completed the required six months 
parasitological follow up period. The respective cure rates in accordance with 
the oogram, HPJ and K-K findings were: 29.2%, 50% and 91.7% for praziquan­
tel; 22.7%, 50% and 86.3% for oxamniquine. Despite a quite low cure rate, a 
sharp fall (-83%) in the mean number of living eggs per gram of tissue was ob­
served in the post-treatment oograms. 
These results indicated that both anti-schistosomal agents were similarly effi­
cacious 
On the other hand, a striking difference in the cure rates amongst the three 
parasitological control methods became evident. The oogram was the most accu­
rate one, followed by HPJ and lastly by K-K. Since there was a direct correla­
tion between the number of living eggs in the oogram and the positivity of the 
stool examinations, the percentage of false-negative results has augmented remar­
kably after treatment reaching 47.3% with HPJ and 92.9% with K-K. Prior to 
therapy they were 0% and 64,8%, respectively. 
The authors infer that the different accuracy of the applied methodology to 
assess therapeutical efficacy may explain the discrepancy between the cure rate 
achieved in this clinical trial and those reported by other investigations with 
either praziquantel or oxamniquine. 
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I N T R O D U C T I O N 
Oxamniquine, a 2 aminomethyl tetrahydro-
quinoleine derivative, was selected by BAXTER 
and RICHARDS in 1971 as one of the most pro­
mising schistosomicidal agents2. 
Several authors, mainly in Brazil, have re­
ported excellent therapeutical results with this 
drug in mansoni schistosomiasis despite va­
riable cure rates administering similar doses, 
either to adults or to children, and using the 
same parasitological evaluation method (stool 
examination according to Kato Katz) 4 4 1 , 2 1 , 2 7 , 2 8 , 
On the other hand, when we investigated 
through the quantitative oogram technique the 
efficacy of oxamniquine in a single dose of 15 
to 18 mg/kg bwt in adult patients living away 
from any focus of this infection, contrariwise 
to the papers published so far, we found out 
a quite low (38%) cure rate'2. We concluded 
that although oxamniquine acts against Schis­
tosoma mansoni its activity is only transient. 
In most of the cases the drug reduced the 
worm burden but without being able to sup­
press the persistence of the parasitosis. 
Praziquantel, a novel schistosomicidal 
agent, is a low toxicity isoquinoline-pyrazine 
compound active against all schistosome spe­
cies pathogenic to man, namely S. mansoni, S. 
haematobium and S. japonicum i.i6,n,36. More 
over, in the treatment of experimental as well 
as human schistosomiasis this drug proved to 
be highly efficatious 7 , 8 , 1 4 , 1 9 , 2 2 , 2 3 , 3 0 , 3 1 , 3 3 . 
Double-blind clinical trials comparing pra­
ziquantel with oxaminiquine in single doses ha­
ve been carried out as well, revealing no signi­
ficant difference between their efficacy in 
accordance with the evaluation by stool exami­
nations following the KatoKatz method 5,15, 
24,25. 
On the other hand, in consequence of di­
vergent findings attained by us with oxamni­
quine in previous therapeutical evaluation ba­
sed on the quantitative oogram, we decided to 
undertake a double blind clinical trial using 
this same technique to compare these two anti-
sehistosome agents. In addition stool exami­
nation according to both, Hoffmann, Pons & 
Janer and Kato-Katz methods, were performed 
to confront the accuracy of these different pa­
rasitological methods in the diagnosis and in 
the assessment of therapeutical efficacy. 
PATIENTS AND METHODS 
A total of 54 patients, 52% males and 48% 
females, in between 15 and 55 years of age, 
weighting from 38 to 86 kg, were forwarded to 
our out patient clinical having a previously po­
sitive stool examination for S. mansoni eggs. 
They presented the intestinal (54%) or hepa-
to intestinal (46%) form of chronic schistoso­
miasis and have not been treated yet with any 
speciifc medication. All of them lived in the 
city of Belo Horizonte, away from contact -with 
any focus of this infection and they were ins­
tructed not to return to endemic areas during 
the six months subsequent to the treatment. 
Pregnant or nursing women, patients with as­
sociated liver, kidney, lung or heart disease, 
acute or severe chronic illnesses, as well as 
marked anemia or nutritional deficiencies, were 
excluded from the trial. 
Following the parallel group design, the 
patients upon entering the trial were allocat­
ed into one of two groups which distribution 
according to age, sex body weight, clinical form 
of the disease and worm burden (as determin­
ed by the quantitative oogram findings) is dis­
closed in Table I . Both groups had an equal 
number of cases (27 patients) and were homo­
geneous regarding these features. One was 
treated with praziquantel and the other with 
oxamniquine, in accordance with a double blind 
administration. The two drugs were dispensed 
in individually coded bottles and presented in 
capsules of identical appearence but containing 
different dosages — praziquantel 325 mg and 
oxamniquine 90 mg. Therefore, the number 
of capsules to be taken in relation to each pa­
tient's bodyweight was the same for either 
drug to reach an average dose of 65 mg/kg and 
18 mg/kg, respectively. The total medication 
was administered in a single dose divided into 
two intakes, four hours apart, always at morn­
ing, under the direct supervision of the nurses. 
The double-blind code was provided prior to 
the beginning of the study within sealed enve-
lopes, for each case, to be opened only at the 
end of the trial. 
Prior to treatment all patients were sub­
mitted to rectal mucosa biopsy for performing 
a quantitative oogram6. Except for eight cases 
in whom the number of living S. mansoni eggs 
per gram of tissue ranged from 1,085 to 1,926, 
all others had more than 2.000 eggs. The 
stool examination was repeated according to 
the spontaneous sedimentation HOFFMAN, 
PONS & JANER 1 3 method (HPJ) and the quan­
titative Kato method modified by KATZ 2 0 
(K-K). The former was performed along the 
established classical procedures and the latter 
using the Vermifec® kit from Boehringer 
Mannheim. Three slides were taken of each 
stool sample and the arithmetical mean of the 
countings indicated the result of the examina­
tion. As demonstrated in Table II , whereas the 
HPJ was positive in all cases in relation to the 
oogram results, the K K was positive only in 
35.2% of them. 
The control of parasitological cure at the 
end of 1, 2, 4 and 6 months after the drug 
administration included quantitative oogram 
evaluation, as well as stool examinations in 
conformity to both aforementioned methods. In 
addition, rectal mucosa biopsies were taken 
on the 6th. and 18th. days following the treat­
ment, in a limited number of patients, that is, 
9 patients with the praziquantel and 5 patients 
with the oxamniquine, to verify the immediate 
effect of the therapy and its coefficient of va­
riation 9 . 
On the day of treatment the patients under­
went a thorough physical examination and re 
mained under observation during six to eight 
hours after the drug intake to look for any ad 
verse drug reaction. Two days afterwards they 
returned to the outpatient clinic to be investi 
gated concerning the occurrence of late side-ef 
fects. 
RESULTS 
Tolerability — The occurrence of side-
effects is displayed in Table I I I . Their inciden­
ce, severity and duration were similar for both 
drugs. They occurred in 43% of the patients, 
were mostly (88%) of slight to moderate in­
tensity and did not last longer than four hours 
in 28% of the cases, than eight hours in 47% 
and than 24 hours in 98%. Usually (91%), they 
appeared within the first four hours subse­
quent to the drug intake and all of them disap­
peared spontaneously without any medication. 
The main complaints were dizziness (24%), 
drowsiness (15%), heartburn (15%), general 
malaise (15%) and nausea (11%). The first 
two had a tendence to be more frequently ob­
served under oxamniquine and the last two 
under praziquantel. On the fifth day after 
taking this drug one patient developed eosino-
phic pneumonitis, Loefler Syndrome, diagnosed 
by X-Ray and laboratorial examinations. 
Efficacy — In order to investigate the im­
mediate effect of the two drugs on the egg 
laying capacity of S. mansoni, quantitative 
oograms were performed on the 6th. and 18th. 
days after therapy in nine patients treated with 
praziquantel and in five with oxamniquine. The 
method's coefficient of variation (CV) was 
then calculated. It ranged from 103 to 171% 
with the former drug and from 99 to 164% 
with the latter one, as shown in Table IV. The 
Graphics 1 2 and 3 illustrate three examples 
from the praziquantel group and Graphics 4, 
5 and 6, three from the oxamniquine group. 
They also indicate the outcome of the treat­
ment, recurrence or cure, at the end of the 
six month follow up. 
In the assessment of the therapeutical effi­
cacy it is noteworthy that the results in regard 
to the three parasitological control methods 
were not concordant. As observed, in Table V, 
in 24 patients who have completed the six 
month follow up out 27 treated with praziquan­
tel the cure rates were: 29.2% (7/24) according 
to the oogram; 50.0% (12/24) to the HPJ and 
91.7% (22/24) to the K-K. In the 22 controlled 
patients out of 27 treated with oxamniquine 
these rates were 22.7% (5/22), 50.0% (11/22) 
and 86.3% (19/22), respectively. 
On the other hand, the mean number of 
living eggs per gram of tissue taken by biopsy 

of the rectal mucosa prior to treatment in the 
two groups, 3,348, has decreased to 571 follow­
ing the drug administration, meaning a reduc­
tion of 83% in the worm burden, as indicated 
in Table VI (54 cases before the treatment and 
112 cases with living eggs in the oograms after 
the treatment). 
Furthermore, the relationship between the 
number of living S. mansoni eggs found in the 
quantitative oograms and the positivity of the 
correspondent stool examinations, before as 
well as after treatment with either praziquan­
tel or oxamniquine, was established. It beca­
me evident, as displayed in Table VII, that 
there is a direct correlation between both tech­
niques; the greater the number of living eggs 
per gram of tissue taken by biopsy of the rec­
tal mucosa, the higher the percentage of posi­
tive findings in the stool examination. However. 
the K-K method showed a lower sensitivity 
than the HPJ method. When the number of 
eggs in the oorgram was above 2,000 the HPJ 
was positive in 100% of the cases but the K K 

in 25.6%, between 1,000 and 2,000 the HPJ was 
positive in 66.7% and the K-K in 9.1% below 
1,000 the HPJ was positive in 38% and the K-K 
only in 6%. 
Such correlation is also illustrated by Fi­
gure A for both treatment groups. It demons­
trates that the reduction in the number of li­
ving eggs in the oogram consequent to the 
treatment leads to a diminished positivity of 
the stool examinations. Again, the K-K is asso­
ciated with a higher degree of false negative 
results 92.9% than the HPJ method 47.3%. 

DISCUSSION 
Prom our point-of view the therapeutical 
evaluation of new drugs for treating human 
schistosomiasis mansoni should be accompli­
shed through the quantitative oogram via rec­
tal mucosa biopsies due to the trusfcworthness 
of this method W ° . 
The therapeutic effects of schistosomicides 
have an initial phase (shift of worms from me­
senteric veins to the liver) and a second phase 
(ensheathment, degeneration and phagocytosis 
in the liver) which depends upon the time the 
worms are in the liver. If the worms are not 
killed, remigration to the mesenteric veins will 
occur. Since there is normally a continuity in 
the process of egg-laying by females, the first 
result of an active drug is to cause interruption 
of oviposition with consequent alterations in 
the oogram. Because no drug acts on the eggs 
themselves they continue their development in 
the tissue up to maturation and elimination in 
the stools. After some time no immature egg 
is observed. If the effect of the drug is of short 
duration or temporary-just sufficient to pro­
duce a major shift of the worms from mesen­
teric veins to the liver-hut does not kill the 
worms, remigration to the mesenteric veins 
occurs and the oogram will show re establish­
ment of oviposition some time later, with reap-
perance of viable eggs, giving a picture o cli­
nical relapse. If this does not occur and the 
effect is definitive, there is cure. Indeed, if 
the suppresion lasts longer than six months a 
parasitological cure is achieved. 
When the drug does not act on the worms 
—• i.e., when it is inactive — no alteration of 
the distribution of the worms in the portal sys­
tem is produced and the oogram will not chan­
ge; this is treatment failure. 
Finally, some drugs are partially active 
During treatment some worms which did not 
shift to the liver may remain in the intestinal 
venules andi maintain oviposition, which of 
course, will be reduced. There is a significant 
reduction, both immature and mature living 
eggs but not their disappearence in the oograms 
subsequent to the treatment. 
In case of either a partially or a transient 
active drug, modifications whithin the chemi-
cal structure of the substance could be made 
in order to obtain a definitive active anti-schis-
tosome agent. 
Under this standpoint and taking into 
account the results of our clinical trial, both 
drugs have proved to be partial or transient 
active substances against S. mansoni infection, 
although in the few cured cases their action 
has been a definitive one. Actually, we already 
had demonstrated this fact in regard to oxam 
niquine 1 1 , 1 2 , 2 7 . The current findings showing 
a C.V. greater than 60% (from 99 to 164%) 
have confirmed it once again. Praziquantel was 
a potent agent being able to interrupt egg lay-
ing in practically all patients with a C.V. 
rangeing from 103 to 171%. Solely in one case 
there was an incomplete egg laying suppres-
sion, immature living eggs being found until 
the 18th. day after the drug intake, in spite of 
a C.V. of 127% (Table I V ) . Considering the 
results of previous experimental studies invol-
ving praziquantel 3 - 2 6 , we believe that it would 
be feasible to render it a definitive acting schis-
tosomicidal agent in almost all cases if its ad-
ministration is prolonged beyond a single day 
treatment using this same daily dose. To con-
firm such assumption would mean an impor-
tant objective, particularly in view of this drug 
being active against S. mansoni strains resis-
tant to oxamniquine13. 
At the end of the six month follow up the 
cure rates according to the oogram findings 
were 29% with praziquantel and 23% with 
oxamniquine, that is, a recurrence rate of 71% 
and 77%, respectively. It should be emphasiz-
ed that although these cure rates were quite 
low, there was a marked decrease (83%) in the 
mean number of living eggs in the non-cured 
cases, leaving no doubt about an obvious re-
duction of the parasitic load induced by the 
treatment with either drug. Hence, the effica-
cy of the two agents was similar, in agreement 
with reports from other investigators 5 , 1 5 , 2 4 , 2 5 , 
However, the recurrences observed after oxam-
niquine occurred invariably between the first 
and second months whilst it took a little lon-
ger, between the second and third months, 
after praziquantel. Since all patients did not 
came into contact with any focus of this infec-
tion during the parasitological control period, 
one can dismiss the possibility of reinfections. 
The oograms in the cured patients showed 
absence of living eggs and reduction or so-
metimes disappearence of dead ones. Firstly 
the recently dead, then the calcified eggs and 
later the granulomas disappeared. In the non-
cured case, dead eggs — recently and calcified 
ones as well as granulomas — were always 
present besides the living eggs. 
On the other hand, in accordance with 
stool examinations the cure rates were: 50% for 
both drugs using the HPJ method; 92% with 
praziquantel and 86% with oxamniquine using 
the K-K method. Therefore, a clear difference -
in the percentage of cure was observed amongst 
the three methods. The oogram proved to be 
the most accurate one, followed by HPJ and 
lastly by K-K. 
Prior to therapy, the oogram and the HPJ 
were positive in 100% of the cases but the KrK 
only in 35%. Since the positivity of the stool 
examinations correlates directly with the num-
ber of living eggs in the oogram, ¿he accuracy 
of both HPJ and K-K has diminished markedly 
following the sharp fall of these eggs caused 
by treatment. For 112 (110%) positive oograms 
subsequent to therapy, the HPJ was positive 
in only 53% of the cases and the K-K in no 
more than 7%. Due to this rather high fre-
quency of false-negative results (93,0%) observ-
ed with K K , a question is rased on the validity-
of using this method in clinical trials to esta-
blish the efficacy of new drugs. 
Confronting our results, according to the 
oogram findings, with those from other inves-
tigations based on stool examinations, a re-
markable difference in the therapeutical effi-
cacy becomes evident. Such discrepancy in 
cure rates already has been pointed out in our 
previous study involving oxamniquine12. Con-
cerning praziquantel, several authors have re-
ported relatively high cure rates: 84.4% with 
2 x 25 mg/kg in hepatosplenic cases8; 92.0% 
with 1 x 50 mg/kg and 97.0% with 3 x 20 
mg/kg22; 93.3% in acute cases and 87.5% in 
chronic ones with 2 x 25 mg /kg94 .4% with 
1 x 40 mg/kg in hepatosplenic cases33. If we 
also would rely solely on the figures from the 
K-K method the cure rate achieved in our 
study, 91.7%, is similar to these. Consequen-
tly, we may infer that the divergence between 
our therapeutical results, either with praziquan-
tel or oxamniquine, and those refered by other 
investigators, stem from the different accuracy 
of the applied methodology for assessing pa-
rasitological cure. 
In our opinion, the quantitative oogram is 
the most reliable technique for the evaluation 
of new schistosomicidal agents in man and a 
methodological uniformity regarding the para-
sitológica! control of cure should be reached 
to avoid divergent interpretations about the-
rapeutical efficacy of drugs. 
RESUMO 
Avaliação terapêutica duplo-cega baseada na 
técnica do oograma quantitativo, comparando 
praziquantel com oxamniquine na Esquistosso¬ 
mose mansônica humana. 
Um total de 54 pacientes adultos, com es¬ 
quistossomose mansônica crônica, nas formas 
intestinal ou hepatintestinal, participou de um 
ensaio clínico duplo-cego, para comparar o pra-
ziquantel com a oxamniquine. De acordo com 
uma distribuição aleatória, 27 casos receberam 
o praziquantel (65 mg/kg de peso corporal) 
e 27 a oxamniquine (18 mg/kg), administrados 
em dose oral única. 
A incidência, intensidade e duração dos 
efeitos colaterais foram similares para os dois 
medicamentos A avaliação da eficácia tera-
pêutica baseou se na técnica do oograma quan-
titativo por biópsia da mucosa retal, realizada 
ao final de um, dois, quatro e seis meses de-
pois do tratamento. Nessas mesmas ocasiões 
foram feitos exames de fezes pelos métodos 
de HOFFMAN, PONS e JANER e de KATO-
KATZ, com a finalidade de confrontar seu re-
sultados com os achados do oograma. Para 
averiguar o efeito imediato do tratamento so-
bre a atividade ovipositora do parasito, um nú-
mero restrito de pacientes foi submetido a 
biópsias retáis no 6,° e 18.° dias subsequentes a 
administração da medicação. 
Ambas as drogas provaram ser ativas con-
tra o esquistossoma, vez que os respectivos 
coeficientes de variação, determinados a par-
tir de oogramas efetuados imediatamente após 
o tratamento, foram superiores a 60%. Ade-
mais, dentre os 27 pacientes de cada grupo, 24 
tratados com praziquantel e 22 com oxamni-
quine completaram o período de seis meses, 
requerido para controle parasitológico. 
Os índices de cura, segundo os achados do 
oograma e dos exames de fezes pelos métodos 
de HPJ e K K , foram, respectivamente, 29%,— 
50% e 92% com o praziquantel; 23%, 50% e 
86% com a oxamniquine. Apesar do baixo 
percentual de cura, observou-se nos oogramas 
pós tratamento, uma pronunciada queda no nú-
mero de ovos vivos por grama de tecido. 
Esses resultados revelam que ambas as 
drogas foram semelhantemente eficazes, embo-
ra já se tenha comprovado que a susceptibili¬ 
dade do S. mansoni não seja sempre igual pa-
ra cada um desses medicamentos, pois linha-
gens resistentes à oxamniquine evidenciaram 
ser 100% sensíveis ao praziquantel. 
Por outro lado, constatou-se uma nítida 
diferença nos percentuais de cura em função 
do método utilizado para controle parasitoló-
gico. O oograma foi o mais preciso, seguido 
pelo HPJ e, finalmente, pelo K-K. Tendo ocor-
rido uma correlação direta entre o número de 
ovos vivos no oograma e a positividade dos 
exames de fezes, a percentagem de resulta-
dos falso-negativos aumentou acentuadamente 
após o tratamento, alcançando 47,3% com o 
HPJ e 92,9% com o K-K. Antes da medicação 
esses índices eram, respectivamente, 0% e 
64,8%. 
Os autores depreendem que a diferença de 
precisão da metodologia aplicada para avaliar 
a eficácia terapêutica pode explicar a diver-
gência encontrada entre o índice de cura ob-
tido neste - ensaio clínico e os relatados por 
outros investigadores, tanto com o praziquan-
tel quanto com a oxamniquine. 
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